Literature DB >> 36087230

In Vitro and In Vivo Comparative Analysis of Differentially Expressed Genes and Signaling Pathways in Breast Cancer Cells on Interaction with Mesenchymal Stem Cells.

Hariharan Jayaraman1, Ashwin Anandhapadman1, Nalinkanth Veerabadran Ghone2.   

Abstract

The interaction of breast cancer cells (BCC) with mesenchymal stem cells (MSC) plays a vital role in influencing the gene expression in breast cancer cells and thereby its uncontrolled proliferation, metastasis, and drug resistance. The extent of MSC governing the BCC or the extent of BCC influencing the MSC is a complex process, and the interaction strongly depends upon conditions such as the presence or absence of other cell types and in vivo tumor microenvironment or simple in vitro conditions. Hence, understanding this interaction through gene expression profiling may provide key insights about potential genes which can be targeted for breast cancer treatment. In the current study, in vitro microarray dataset and in vivo RNA-seq dataset of BCC on interaction with the MSC were downloaded from NCBI GEO database and analyzed for differentially expressed genes (DEGs), gene ontology (GO) term enrichment, and Reactome pathway analysis. To target the genes which have similar effect on both in vitro and in vivo, a comparative analysis was performed, 24 genes were commonly upregulated in both in vitro and in vivo datasets, while no common downregulated genes were observed. Out of which, 16 significant genes based upon fold change (logFC > 2) are identified for manipulating the interactions between MSC and BCC. Among them, 6 of the identified genes (FSTL1, LOX, SERPINE1, INHBA, FN1, and VEGFA) have already been reported to be upregulated in BCC on interaction with MSC by various studies. Further experiments need to be conducted to understand the role of remaining 10 identified genes (EFEMP1, IGFBP3, EDIL3, IFITM1, IGFBP4, ITGA5, SLC3A2, HRH1, PPP1R15A, and NNMT) in MSC-BCC interaction. In addition to the reported significant genes and its associated pathways, the expression of long non-coding RNA identified in this study may increase our understanding about the way MSC interacts with BCC and accelerate MSC-based treatment strategies for breast cancer.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Breast cancer cells; Differentially expressed genes; In vitro; In vivo; Mesenchymal stem cells; Signaling pathways

Year:  2022        PMID: 36087230     DOI: 10.1007/s12010-022-04119-9

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   3.094


  67 in total

1.  Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-β1 and upregulate expression of regulatory molecules on T cells: do they protect breast cancer cells from the immune response?

Authors:  Mahboobeh Razmkhah; Mansooreh Jaberipour; Nasrollah Erfani; Mojtaba Habibagahi; Abdol-rasoul Talei; Abbas Ghaderi
Journal:  Cell Immunol       Date:  2010-09-27       Impact factor: 4.868

2.  Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma.

Authors:  Xiang H-F Zhang; Xin Jin; Srinivas Malladi; Yilong Zou; Yong H Wen; Edi Brogi; Marcel Smid; John A Foekens; Joan Massagué
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

Review 3.  Epidemiology of breast cancer in Indian women.

Authors:  Shreshtha Malvia; Sarangadhara Appalaraju Bagadi; Uma S Dubey; Sunita Saxena
Journal:  Asia Pac J Clin Oncol       Date:  2017-02-09       Impact factor: 2.601

4.  Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta.

Authors:  Shyam A Patel; Justin R Meyer; Steven J Greco; Kelly E Corcoran; Margarette Bryan; Pranela Rameshwar
Journal:  J Immunol       Date:  2010-04-09       Impact factor: 5.422

5.  Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT).

Authors:  F T Martin; R M Dwyer; J Kelly; S Khan; J M Murphy; C Curran; N Miller; E Hennessy; P Dockery; F P Barry; T O'Brien; M J Kerin
Journal:  Breast Cancer Res Treat       Date:  2010-01-20       Impact factor: 4.872

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

7.  The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer.

Authors:  Zhenbo Tu; Johannes Schmoellerl; Odette Mariani; Yurong Zheng; Yi Hu; Anne Vincent-Salomon; Antoine E Karnoub
Journal:  NPJ Breast Cancer       Date:  2021-05-31

8.  Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma.

Authors:  Aarif Y Khakoo; Shibani Pati; Stasia A Anderson; William Reid; Mohamed F Elshal; Ilsa I Rovira; Ahn T Nguyen; Daniela Malide; Christian A Combs; Gentzon Hall; Jianhu Zhang; Mark Raffeld; Terry B Rogers; William Stetler-Stevenson; Joseph A Frank; Marvin Reitz; Toren Finkel
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

9.  From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline.

Authors:  Yunshun Chen; Aaron T L Lun; Gordon K Smyth
Journal:  F1000Res       Date:  2016-06-20

Review 10.  Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.

Authors:  Andrew McGuigan; Paul Kelly; Richard C Turkington; Claire Jones; Helen G Coleman; R Stephen McCain
Journal:  World J Gastroenterol       Date:  2018-11-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.